Page 198 - Read Online

Page 10 of 11 Nakamura et al. Hepatoma Res 2019;5:16 I http://dx.doi.org/10.20517/2394-5079.2019.06

Availability of data and materials
The original raw data used to support the findings of this study have not been made available because of the risk
that will come into conflict with Personal Information Protection Law in Japan.

Financial support and sponsorship
Not applicable.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2019.

REFERENCES
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108.
2. CBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific
mortality for 240 causes of death, 1990-2013: a systematic analysis for the global burden of disease study 2013. Lancet 2015;385:117-71.
3. Kanwal F, Hoang T, Kramer JR, Asch SM, Goetz MB, et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis
C virus infection. Gastroenterology 2011;140:1182-8.
4. Reig M, Mariño Z, Perelló C, Iñarrairaegui M, Ribeiro A, et al. Unexpected high rate of early tumor recurrence in patients with
HCV-related HCC undergoing interferon-free therapy. J Hepatology 2016;65:719-26.
5. Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related
cirrhosis treated with direct-acting antivirals. J Hepatol 2016;65:727-33.
6. Waziry R, Hajarizadeh B, Grebely J, Amin J, Law M, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy:a
systematic review, meta-analyses, and meta-regression. J Hepatol 2017;67:1204-12.
7. Nagata H, Nakagawa M, Asahina Y, Sato A, Asano Y, et al. Effect of interferon-based and -free therapy on early occurrence and
recurrence of hepatocellular carcinoma in chronic hepatitis C. J Hepatol 2017;67:933-9.
8. Romano A, Angeli P, Piovesan S, Noventa F, Anastassopoulos G, et al. Newly diagnosed hepatocellular carcinoma in patients with
advanced hepatitis C treated with DAAs: a prospective population study. J Hepatol 2018;69:345-52.
9. Ikeda K, Kawamura Y, Kobayashi M, Kominami Y, Fujiyama S, et al. Direct-acting antivirals decreased tumor recurrence after initial
treatment of hepatitis C virus-related hepatocellular carcinoma. Dig Dis Sci 2017;62:2932-42.
10. ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts).
Electronic address: stanislas.pol@aphp.fr1. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular
carcinoma: data from three ANRS cohorts. J Hepatol 2016;65:734-40.
11. Huang AC, Mehta N, Dodge JL, Yao FY, Terrault NA. Direct-acting antivirals do not increase the risk of hepatocellular carcinoma
recurrence after local-regional therapy or liver transplant waitlist dropout. Hepatology 2018;68:449-61.
12. Ooka Y, Miho K, Shuntaro O, Nakamura M, Ogasawara S, et al. Prediction of the very early occurrence of HCC right after DAA therapy
for HCV infection. Hepatol Int 2018;12:523-30.
13. Minami T, Tateishi R, Nakagomi R, Fujiwara N, Sato M, et al. The impact of direct-acting antivirals on early tumor recurrence after
radiofrequency ablation in hepatitis C-related hepatocellular carcinoma. J Hepatol 2016;65:1272-3.
14. Emamaullee JA, Bral M, Meeberg G, Montano-Loza AJ, Bain VG, et al. HCV eradication with direct-acting antivirals does not impact
HCC progression on the waiting list or HCC recurrence after liver transplantation. Can J Gastroenterol Hepatol 2019;2019:2509059.
15. Zanetto A, Shalaby S, Vitale A, Mescoli C, Ferrarese A, et al. Dropout rate from the liver transplant waiting list because of hepatocellular
carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals. Liver Transpl 2017;23:1103-12.
16. Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma.
J Hepatol 2017; doi: 10.1016/j.jhep.2017.08.030.
17. Claudon M, Dietrich CF, Choi BI, Cosgrove DO, Kudo M, et al. Guidelines and good clinical practice recommendations for Contrast
Enhanced Ultrasound (CEUS) in the liver - update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of
AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasound Med Biol 2013;39:187-210.